Kwanan nan, binciken Antengene's Phase I/II CLINCH na ATG-022 (CLDN18.2 antibody-drug conjugate), wani tsofaffi majiyyaci da ke fama da ciwon daji na ciki wanda ya ci gaba da samun nau'ikan chemotherapy da yawa, immunotherapy da kuma maganin da aka yi niyya duk da yawan metastases da suka yi, ya sami cikakken amsa (CR) bayan maganin ATG-022 guda ɗaya. PET/CT ta tabbatar da yanayin mara lafiyar ba shi da ƙari a watan Mayu na 2025.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
ATG-022 wani nau'in CLDN18.2 ADC ne da Antengene ya gano kuma ya haɓaka a cikin gida. A taron ASCO GI 2025 a farkon wannan shekarar, Antengene ya gabatar da sabbin bayanai na asibiti don ATG-022. A cikin marasa lafiya da ke da matsakaicin amsawar CLDN18.2 (IHC 2+ ≥ 20%), ƙimar amsawar manufa (ORR) shine 42.9%, kuma ƙimar sarrafa cutar (DCR) shine 95.2%. Daga cikin marasa lafiya da ke da ƙarancin amsawar CLDN18.2 (IHC 2+ < 20%), ORR shine 30.0%, kuma DCR shine 50.0%. Waɗannan bayanai sun nuna cewa ATG-022 yana ba da tasiri mai ma'ana a asibiti da kuma kyakkyawan bayanin aminci a cikin matakan bayyanar CLDN18.2, gami da babban amsawar, ƙasa, har ma da ƙarancin amsawar. Aikinsa na maganin ciwon daji mai faɗi ya nuna cewa ATG-022 na iya bayar da fa'idodi na magani ga yawancin marasa lafiya idan aka kwatanta da sauran magungunan da aka yi niyya ga CLDN18.2. A halin yanzu, ana ci gaba da nazarin fadada allurai na mataki na biyu na ATG-022 a babban yankin China da Ostiraliya.
Wannan nasarar da aka samu ta hanyar gwajin CR a cikin wannan tsohuwa mai fama da cutar kansar ciki abin ƙarfafa gwiwa ne ƙwarai, yana nuna yuwuwar maganin ATG-022 a matsayin sabuwar hanyar magance cutar ADC. Abu mai mahimmanci, wannan ba shine kawai CR da aka lura a cikin binciken da ake ci gaba da yi ba. Zuwa yanzu, an lura da shari'o'in CR guda uku, ciki har da marasa lafiya daga babban yankin China da Ostiraliya. Antengene na fatan gabatar da sabbin bayanai daga binciken ATG-022 a taron ESMO mai zuwa a watan Oktoba 2025.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lokacin Saƙo: Agusta-21-2025